This experiment proposed that desipramine, in combination with TRAIL, plays a role as an anti-cancer agent that can be employed to enhance the sensitivity of lung cancer cells towards TRAIL-induced apoptosis. This evidence concerns the gene TNFSF10 and lung carcinoma.